Note: Ingredients listed on restricted chemical lists
General Information
Revision date
2020-03-30
Product name
Aservo EquiHaler
Product Synonyms
Ciclesonide 30 mg/mL Inhalation Solution for horses
1.2.1 Relevant identified uses
Medicine
1.2.2. Uses advised against
Safety Data Sheet only for the professional user on use
Emergency telephone
+1 703-527-3887 Chemtrec 24-hours
Icons in SDS
Company Information
company name
Boehringer Ing. Pharma GmbH & Co. KG
e-mail address of the competent person responsible for the Safety Data Sheet
EHS-Services@Boehringer-Ingelheim.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H225, H319, H361d
Hazard statements
Code
Statements
H225
Highly Flammable liquid and vapour
Section 2
CLP CLASSIFICATION
Flammable liquids , Category 2 H225: Highly flammable liquid and vapour. Eye irritation , Category 2 H319: Causes serious eye irritation. Reproductive toxicity , Category 2 H361d: Suspected of damaging the unborn child.
2.2 Label elements
REGULATION (EC) No 1272/2008)
Signal word
Danger
Hazard statements
H225 Highly flammable liquid and vapour. H319 Causes serious eye irritation. H361d Suspected of damaging the unborn child.
Prevention
P201 Obtain special instructions before use. P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. P233 Keep container tightly closed. P280 Wear protective gloves/ protective clothing/ eye protec- tion/ face protection.
Response
P303 + P361 + P353 IF ON SKIN (or hair): Take off immedi- ately all contaminated clothing. Rinse skin with water. P370 + P378 In case of fire: Use dry sand, dry chemical or alcohol-resistant foam to extinguish.
Hazardous Ingredients
Ciclesonide
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher. This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS) The pharmacological effect of the medicament has to be considered (see package leaflet).
